About US
Contact us
-
Lupin gets off light after FDA inspection at Indian manufacturing plantLupin is no stranger to FDA rebukes, though its latest write-up from the U.S. drug regulator certainly could have been worse for the company. Following an inspection of Lupin’s Pithampur Unit-2 ma2023/7/18
-
FDA clears more chemotherapy imports from China's Qilu amid shortage of key cancer medsAs a shortage of key chemotherapy drugs continues to upend cancer treatment across the country, the FDA has resorted to securing some of the meds from China. After approving2023/7/18
-
FDA rejects Xspray's would-be rival to Bristol Myers' Sprycel on dosing, manufacturing concernsWith Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely. That’s good news for Bristol Myers Squibb, which has secured a few m2023/7/13
-
Samsung Biologics, after expanding Pfizer collab, inks Novartis production deal worth $391MSamsung Biologics, after expanding Pfizer collab, inks Novartis production deal worth $391MJust days after sewing up a pair of $897 million deals with Pfizer, Samsung Biologics has added a few hundred million dollars more to its partnership cash pile—this time courtesy of an expanded pact2023/7/13
-
Novavax to receive $350M from Canada for canceled COVID vaccine ordersAs Novavax works to endure uncertain demand for its COVID-19 vaccine, the company's close relationship with Canada is taking a new form. The country has canceled some COVID-2023/7/11
-
WuXi Bio telegraphs spinoff of its bioconjugate subsidiary XDCAngling for greater independence, it appearsthe time has come for WuXi’s bioconjugation offspring to leave the nest. WuXi Biologics hasunveileda proposed spinoff and separate listing of WuXi XDC C2023/7/11
-
Cipla pulls 6 batches of asthma med albuterol after inhaler leak complaintCipla, which was recently hit with a 23-page Form 483 filing from the FDA, is adding to the albuterol supply strain with a U.S. recall of six batches of the asthma med. The2023/7/7
-
FDA slams Intas, Ipca over manufacturing shortfalls at 3 Indian plantsAfter a pandemic-fueled lull the past few years, FDA inspections are back in full force. This week,a pair of Indian drugmakers have found themselves in the agency’s crosshairs.2023/7/7
-
Teva weighs sale of $2B API business as CEO Richard Francis embarks on 'Pivot to Growth' strategy: reportsLess than two months into its "Pivot to Growth" strategy under a new CEO, Israeli-American generics giant Teva Pharmaceutical could be weighing a major shake-up of its key drug ingredients business.2023/7/5
-
Go for the Gulf: Sanofi partners with local drugmakers to crank out vaccines at new manufacturing plant in Saudi ArabiaAfter AstraZeneca and National Resilience made recent inroads into the United Arab Emirates, Sanofi has emerged as the next pharmaceutical giant setting its sights on the Middle East.2023/7/5